Pre-Made Taldefgrobep Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Taldefgrobep Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Taldefgrobep alfa is a Immunoglobulin g1 (human fc fragment) fused with adnectin, anti-(human growth differentiation factor 8) (human clone bms-986089 fibronectin tenth type iii domain-derived), dimer. Taldefgrobep alfa is a modified adnectin designed to specifically bind to myostatin (GDF-8). Adnectins is a therapeutic class based human fibronectin, an extracellular protein that is naturally abundant in human serum. Taldefgrobep alfa used for the treatment of neurologic, neuroinflammatory, and neuropsychiatric disorders.
| Products Name (INN Index) | Pre-Made Taldefgrobep Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP |
|---|---|
| INN Name | taldefgrobep alfa |
| Target | MSTN |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – IGHG1 Fc (Fragment constant) – [peptidyl linker – Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10)]2 |
| VD LC | Fusion – IGHG1 Fc (Fragment constant) – [peptidyl linker – Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10)]2 |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Bristol-Myers Squibb (Princeton NJ USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Alternative to antigen receptors, domain scaffold FN1 F10, fibronectin F10 (Adnectin?) |
| Previous Name | NA |
| Gm Offical Target Name | MSTN |
| Package |
